Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine

2013/07/01 by Julie A. Johnson, Larisa H. Cavallari · 134 citations
Medicine · Pharmacology, Toxicology and Pharmaceutics · #Antiplatelet Therapy and Cardiovascular Diseases #Bioinformatics #Biology #CYP2C9 #Disease #Genetics #Hormonal Regulation and Hypertension #Intensive care medicine #Internal medicine #Medicine #Pathology #Personalized medicine #Pharmacogenetics #Pharmacogenetics and Drug Metabolism #Pharmacogenomics #Pharmacology #Precision medicine #VKORC1 #Warfarin

paper · open access · doi:10.1124/pr.112.007252

published in Pharmacological Reviews 65(3), 987-1009 (American Society for Pharmacology and Experimental Therapeutics)

openalex publication_date 2013/07/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Citations

• CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
• Cardiovascular Pharmacogenomics

Cited by

• Atrial fibrillation
• Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response. [europepmc]
• Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. [europepmc]
• Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet response. [europepmc]
• Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). [europepmc]
• Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not? [europepmc]
• State of Art of Cancer Pharmacogenomics in Latin American Populations. [europepmc]
• CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. [europepmc]
• Multiplex biomarker approach to cardiovascular diseases. [europepmc]
• Clinical Pharmacogenomics: Applications in Nephrology. [europepmc]
• Aspirin & clopidogrel non-responsiveness & its association with genetic polymorphisms in patients with myocardial infarction. [europepmc]
• Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. [europepmc]
• Pharmacogenomics In Pharmacy Practice: Current Perspectives. [europepmc]
• Basic Concepts in Genetics and Pharmacogenomics for Pharmacists. [europepmc]
• Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients. [europepmc]
• Role of Genetic Variations in the Hepatic Handling of Drugs. [europepmc]
• Pharmacogenomics for Primary Care: An Overview. [europepmc]
• Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay. [europepmc]
• The Interface of Therapeutics and Genomics in Cardiovascular Medicine. [europepmc]
• Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management? [europepmc]
• Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. [europepmc]
• Gypenoside XVII protects against myocardial ischemia and reperfusion injury by inhibiting ER stress-induced mitochondrial injury. [europepmc]
• Roles of light transmission aggregometry and CYP2C19 genotype in predicting ischaemic complications during interventional therapy for intracranial aneurysms. [europepmc]
• Drug-microbiota interactions: an emerging priority for precision medicine. [europepmc]
• Being precise with anticoagulation to reduce adverse drug reactions: are we there yet? [europepmc]
• Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review. [europepmc]